Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
(6) male participants must be sterile, sexually inactive, or agree not to father a child during the study and one month after the last dose of study medication, and must agree to use a barrier method for contraception
The first licensed agent, talimogene laherparepvec (T-VEC), administered intratumorally, replicates within tumours to lyse infected cells while expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) to prime systemic immunity
Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes
Cline MG, Burns KM, Coe JB, et al
Not feeling your best
US$ 28.93
US$ 29.89
US$ 20.86
US$ 20.78
US$ 28.12
US$ 21.38
